Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ischemic Heart Disease

  Free Subscription

Articles published in
Lancet
    November 2017
  1. PRABHAKARAN D, Anand S, Watkins D, Gaziano T, et al
    Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.
    Lancet. 2017 Nov 3. pii: S0140-6736(17)32471.
    >> Share

  2. AL-LAMEE R, Thompson D, Dehbi HM, Sen S, et al
    Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Lancet. 2017 Nov 1. pii: S0140-6736(17)32714.
    >> Share

    October 2017
  3. VARENNE O, Cook S, Sideris G, Kedev S, et al
    Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
    Lancet. 2017 Oct 31. pii: S0140-6736(17)32713.
    >> Share

  4. BYRNE RA, Schuster T
    Biodegradable polymer drug-eluting stents: caveat emptor.
    Lancet. 2017;390:1814-1816.
    >> Share

    September 2017
  5. LEAR SA, Hu W, Rangarajan S, Gasevic D, et al
    The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.
    Lancet. 2017 Sep 21. pii: S0140-6736(17)31634.
    >> Share

    August 2017
  6. DEHGHAN M, Mente A, Zhang X, Swaminathan S, et al
    Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study.
    Lancet. 2017 Aug 28. pii: S0140-6736(17)32252.
    >> Share

  7. MILLER V, Mente A, Dehghan M, Rangarajan S, et al
    Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study.
    Lancet. 2017 Aug 28. pii: S0140-6736(17)32253.
    >> Share

  8. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
    Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
    >> Share

  9. KANDZARI DE, Mauri L, Koolen JJ, Massaro JM, et al
    Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32249.
    >> Share

  10. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
    Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
    Lancet. 2017;390:747-759.
    >> Share

  11. CUISSET T, Verheugt FWA, Mauri L
    Update on antithrombotic therapy after percutaneous coronary revascularisation.
    Lancet. 2017;390:810-820.
    >> Share

  12. MINTZ GS, Guagliumi G
    Intravascular imaging in coronary artery disease.
    Lancet. 2017;390:793-809.
    >> Share

  13. THE LANCET
    40 years of percutaneous coronary intervention: where next?
    Lancet. 2017;390:715.
    >> Share

  14. DAMMAN P, de Winter RJ
    Timing of revascularisation for acute coronary syndrome.
    Lancet. 2017 Aug 1. pii: S0140-6736(17)31632.
    >> Share

  15. JOBS A, Mehta SR, Montalescot G, Vicaut E, et al
    Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials.
    Lancet. 2017 Aug 1. pii: S0140-6736(17)31490.
    >> Share

    July 2017
  16. ALI ZA, Serruys PW, Kimura T, Gao R, et al
    2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Lancet. 2017 Jul 18. pii: S0140-6736(17)31470.
    >> Share

    May 2017
  17. RUTTY GN, Morgan B, Robinson C, Raj V, et al
    Diagnostic accuracy of post-mortem CT with targeted coronary angiography versus autopsy for coroner-requested post-mortem investigations: a prospective, masked, comparison study.
    Lancet. 2017 May 24. pii: S0140-6736(17)30333.
    >> Share

    April 2017
  18. KOOPMAN JJE, Kuipers RS
    From arterial ageing to cardiovascular disease.
    Lancet. 2017;389:1676-1678.
    >> Share

  19. KAHAN T
    Target blood pressure in patients at high cardiovascular risk.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30935.
    >> Share

  20. BOHM M, Schumacher H, Teo KK, Lonn EM, et al
    Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30754.
    >> Share

  21. VIDAL-PETIOT E, Bhatt DL, Fox KM, Steg PG, et al
    Blood pressure and cardiovascular outcomes: a closer look - Authors' reply.
    Lancet. 2017;389:1296-1297.
    >> Share

  22. WALD NJ, Wald DS
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1296.
    >> Share

  23. DOUMAS M, Stavropoulos KV, Boutari C, Imprialos KP, et al
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1295-1296.
    >> Share

    March 2017
  24. SCHOOLING CM
    Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?
    Lancet. 2017 Mar 27. pii: S0140-6736(16)31648.
    >> Share

  25. GURBEL PA, Tantry US
    GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30760.
    >> Share

  26. OHMAN EM, Roe MT, Steg PG, James SK, et al
    Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30751.
    >> Share

  27. KAPLAN H, Thompson RC, Trumble BC, Wann LS, et al
    Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study.
    Lancet. 2017 Mar 16. pii: S0140-6736(17)30752.
    >> Share

  28. THE LANCET
    Polypills: an essential medicine for cardiovascular disease.
    Lancet. 2017;389:984.
    >> Share

  29. HUFFMAN MD, Xavier D, Perel P
    Uses of polypills for cardiovascular disease and evidence to date.
    Lancet. 2017;389:1055-1065.
    >> Share

    January 2017
  30. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    Hypertension control and cardiovascular disease - Authors' reply.
    Lancet. 2017;389:154-155.
    >> Share

  31. JAMES JE
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:154.
    >> Share

  32. MESSERLI FH, Fischer U, Rimoldi SF, Bangalore S, et al
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:153.
    >> Share

  33. TAWAKOL A, Ishai A, Takx RA, Figueroa AL, et al
    Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study.
    Lancet. 2017 Jan 12. pii: S0140-6736(16)31714.
    >> Share

    November 2016
  34. COLLINS R, Reith C, Emberson J, Armitage J, et al
    Interpretation of the evidence for the efficacy and safety of statin therapy.
    Lancet. 2016;388:2532-2561.
    >> Share

    October 2016
  35. MAKIKALLIO T, Holm NR, Lindsay M, Spence MS, et al
    Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32052.
    >> Share

  36. MACK M, Holmes DR
    Randomised trials in left main disease: a NOBLE effort.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32067.
    >> Share

  37. VON BIRGELEN C, Kok MM, van der Heijden LC, Danse PW, et al
    Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31920.
    >> Share

  38. FINN AV, Virmani R
    Biodegradable polymer drug-eluting stents: non-inferiority waiting for superiority?
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32063.
    >> Share

  39. ALI ZA, Maehara A, Genereux P, Shlofmitz RA, et al
    Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31922.
    >> Share

  40. SERRUYS PW, Chevalier B, Sotomi Y, Cequier A, et al
    Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32050.
    >> Share

  41. ROSSIGNOL P, Pitt B, Thompson A, Zannad F, et al
    Roadmap for cardiovascular prevention trials in chronic kidney disease.
    Lancet. 2016;388:1964-1966.
    >> Share

  42. GUAN WJ, Zheng XY, Chung KF, Zhong NS, et al
    Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action.
    Lancet. 2016;388:1939-1951.
    >> Share

  43. ISAAZ K, Gerbay A
    Deferred stenting in acute ST elevation myocardial infarction.
    Lancet. 2016;388:1371.
    >> Share

  44. KELBAEK H, Hofsten DE, Engstrom T, Helqvist S, et al
    Deferred stenting in acute ST elevation myocardial infarction - Authors' reply.
    Lancet. 2016;388:1371-1372.
    >> Share

  45. WONG EM, Chair SY, Leung DY, Sit JW, et al
    The effect of an e-health web-based support programme on psychological outcomes and health related quality of life among Chinese patients with coronary heart disease: a parallel-group randomised controlled trial.
    Lancet. 2016;388 Suppl 1:S86.
    >> Share

    September 2016
  46. FEINBERG MW
    No small task: therapeutic targeting of Lp(a) for cardiovascular disease.
    Lancet. 2016 Sep 21. pii: S0140-6736(16)31329.
    >> Share

    August 2016
  47. CAYLA G, Cuisset T, Silvain J, Leclercq F, et al
    Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31323.
    >> Share

  48. VIDAL-PETIOT E, Ford I, Greenlaw N, Ferrari R, et al
    Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31326.
    >> Share

  49. MANCIA G
    Should blood pressure reduction be aggressive in patients with hypertension and coronary artery disease?
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31398.
    >> Share

  50. WEINTRAUB WS
    Invasive management of acute coronary syndromes.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31273.
    >> Share

  51. WALLENTIN L, Lindhagen L, Arnstrom E, Husted S, et al
    Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31276.
    >> Share

  52. REED GW, Rossi JE, Cannon CP
    Acute myocardial infarction.
    Lancet. 2016 Aug 5. pii: S0140-6736(16)30677.
    >> Share

    July 2016
  53. SNYDER A
    Philip Majerus.
    Lancet. 2016;388:458.
    >> Share

  54. KAIN K
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:126.
    >> Share

  55. ETTEHAD D, Emdin CA, Kiran A, Rahimi K, et al
    Blood pressure lowering for cardiovascular disease - Authors' reply.
    Lancet. 2016;388:126-7.
    >> Share

  56. O'KEEFFE DT, Maraka S
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    >> Share

  57. SMULDERS YM, Muller M
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125-6.
    >> Share

  58. COLLINS DR, Albasri A, O'Sullivan J, Bobrovitz N, et al
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    >> Share

  59. STONE GW, Gao R, Kimura T, Simonton C, et al
    Optimum technique to reduce risk of stent thrombosis - Authors' reply.
    Lancet. 2016;388:127-8.
    >> Share

  60. SHAH R
    Optimum technique to reduce risk of stent thrombosis.
    Lancet. 2016;388:127.
    >> Share

    June 2016
  61. GLADWIN MT
    Cardiovascular complications and risk of death in sickle-cell disease.
    Lancet. 2016;387:2565-74.
    >> Share

  62. TEGN N, Abdelnoor M, Aaberge L, Endresen K, et al
    Invasive strategy in acute coronary syndrome - Authors' reply.
    Lancet. 2016;387:2504.
    >> Share

  63. MATHEW ST, Pakala AV, Thadani U
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503-4.
    >> Share

  64. SHAH R
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503.
    >> Share

  65. TIMMIS A
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503.
    >> Share

  66. POVSIC TJ, Zeiher AM
    IxCELL-DCM: rejuvenation for cardiac regenerative therapy?
    Lancet. 2016;387:2362-3.
    >> Share

  67. FUJITA T
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2289.
    >> Share

  68. FORD C, Whitehead SJ, Gama R, Willmer KA, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2289.
    >> Share

  69. SHAH AS, Anand A, Chapman AR, Newby DE, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction - Authors' reply.
    Lancet. 2016;387:2289-91.
    >> Share

  70. BOEDDINGHAUS J, Twerenbold R, Nestelberger T, Wildi K, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2288.
    >> Share

  71. MULLEN L, Chew PG, Frost F, Obafemi T, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2288-9.
    >> Share

  72. DALE A, Slade E, Heneghan C
    Outcomes reporting of the FAME trial.
    Lancet. 2016;387:2292.
    >> Share

    May 2016
  73. LAFONT A, Mennuni MG
    Effect on death of scaffold thrombosis versus stent thrombosis.
    Lancet. 2016;387:2198.
    >> Share

  74. KAUFMAN JD, Adar SD, Barr RG, Budoff M, et al
    Association between air pollution and coronary artery calcification within six metropolitan areas in the USA (the Multi-Ethnic Study of Atherosclerosis and Air Pollution): a longitudinal cohort study.
    Lancet. 2016 May 24. pii: S0140-6736(16)00378.
    >> Share

  75. MENTE A, O'Donnell M, Rangarajan S, Dagenais G, et al
    Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.
    Lancet. 2016 May 20. pii: S0140-6736(16)30467.
    >> Share

  76. SABATE M, Brugaletta S
    Outcomes in the EXAMINATION trial - Authors' reply.
    Lancet. 2016;387:1998.
    >> Share

  77. DRYSDALE H, Hartley P, Goldacre B
    Outcomes in the EXAMINATION trial.
    Lancet. 2016;387:1997-8.
    >> Share

  78. CASSESE S, Kastrati A
    Risk of stent thrombosis with bioresorbable vascular scaffolds - Authors' reply.
    Lancet. 2016;387:1904.
    >> Share

  79. SHAH R, Ramos-Bondy B, Mizeracki A
    Risk of stent thrombosis with bioresorbable vascular scaffolds.
    Lancet. 2016;387:1903.
    >> Share

    April 2016
  80. VESTBO J, Anderson JA, Brook RD, Calverley PM, et al
    Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Lancet. 2016;387:1817-1826.
    >> Share

  81. VAN 'T HOF AW, Ottervanger JP
    Primary angioplasty for STEMI: hard to improve upon.
    Lancet. 2016 Apr 1. pii: S0140-6736(16)30123.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016